Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
George Zogopoulos, Ido Haimi, Shenin A Sanoba, Jessica N Everett, Yifan Wang, Bryson W Katona, James J Farrell, Aaron J Grossberg, Salvatore Paiella, Kelsey A Klute, Yan Bi, Michael B Wallace, Richard S Kwon, Elena M Stoffel, Raymond C Wadlow, Daniel A Sussman, Nipun B Merchant, Jennifer B Permuth, Talia Golan, Maria Raitses-Gurevich, Andrew M Lowy, Joy Liau, Joanne M Jeter, James M Lindberg, Daniel C Chung, Julie Earl, Teresa A Brentnall, Kasmintan A Schrader, Vivek Kaul, Chenchan Huang, Hersh Chandarana, Caroline Smerdon, John J Graff, Fay Kastrinos, Sonia S Kupfer, Aimee L Lucas, Rosalie C Sears, Randall E Brand, Giovanni Parmigiani, Diane M Simeone
BACKGROUND: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. METHODS: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study...
April 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#22
JOURNAL ARTICLE
S-A Safi, A Alexander, W Neuhuber, L Haeberle, A Rehders, T Luedde, I Esposito, G Fluegen, W T Knoefel
BACKGROUND: The implementation of the pathologic CRM (circumferential resection margin) staging system for pancreatic head ductal adenocarcinomas (hPDAC) resulted in a dramatic increase of R1 resections at the dorsal resection margin, presumably because of the high rate of mesopancreatic fat (MP) infiltration. Therefore, mesopancreatic excision (MPE) during pancreatoduodenectomy has recently been promoted and has demonstrated better local disease control, fueling the discussion of neoadjuvant downsizing regimes in MP + patients...
April 16, 2024: Langenbeck's Archives of Surgery
#23
JOURNAL ARTICLE
Austin M Eckhoff, Ashley A Fletcher, Matthew S Kelly, Anders Dohlman, Caitlin A McIntyre, Xiling Shen, Matthew K Iyer, Daniel P Nussbaum, Peter J Allen
OBJECTIVE: We sought to comprehensively profile tissue and cyst fluid in patients with benign, precancerous, and cancerous conditions of the pancreas to characterize the intrinsic pancreatic microbiome. SUMMARY BACKGROUND DATA: Small studies in pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) have suggested that intra-pancreatic microbial dysbiosis may drive malignant transformation. METHODS: Pancreatic samples were collected at the time of resection from 109 patients...
April 16, 2024: Annals of Surgery
#24
EDITORIAL
Ernesto Sparrelid, Poya Ghorbani, Marcus Holmberg
No abstract text is available yet for this article.
April 3, 2024: Hepatobiliary Surgery and Nutrition
#25
JOURNAL ARTICLE
Ning-Ning Ji, Shuang Cao, Xing-Lei Song, Bei Pei, Chen-Yu Jin, Bi-Fa Fan, Hong Jiang, Ming Xia
BACKGROUND: Visceral pain induced by pancreatic cancer seriously affects patients' quality of life, and there is no effective treatment, because the mechanism of its neural circuit is unknown. Therefore, the aim of this study is to explore the main neural circuit mechanism regulating visceral pain induced by pancreatic cancer in mice. METHODS: The mouse model of pancreatic cancer visceral pain was established on C57BL/6N mice by pancreatic injection of mPAKPC-luc cells...
April 3, 2024: Hepatobiliary Surgery and Nutrition
#26
JOURNAL ARTICLE
Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, Simone A Huygens, Winand N M Dinjens, Maureen Rutten-van Mölken
OBJECTIVES: We evaluated the prognostic value of the neurotrophic tyrosine receptor kinase (NTRK) gene fusions by comparing the survival of patients with NTRK+ tumours with patients without NTRK+ tumours. METHODS: We used genomic and clinical registry data from the Center for Personalized Cancer Treatment (CPCT-02) study containing a cohort of cancer patients who were treated in Dutch clinical practice between 2012 and 2020. We performed a propensity score matching analysis, where NTRK+ patients were matched to NTRK- patients in a 1:4 ratio...
April 14, 2024: Molecular Diagnosis & Therapy
#27
REVIEW
Shweta Subhash Giri, Alok Shiomurti Tripathi, Pınar Erkekoğlu, Magdi E A Zaki
The pancreas is a heterocrine gland that has both exocrine and endocrine parts. Most pancreatic cancer begins in the cells that line the ducts of the pancreas and is called pancreatic ductal adenocarcinoma (PDAC). PDAC is the most encountered pancreatic cancer type. One of the most important characteristic features of PDAC is neuropathy which is primarily due to perineural invasion (PNI). PNI develops tumor microenvironment which includes overexpression of fibroblasts cells, macrophages, as well as angiogenesis which can be responsible for neuropathy pain...
April 2024: Journal of Biochemical and Molecular Toxicology
#28
REVIEW
Kyounghyun Kim
The aryl hydrocarbon receptor (AHR) serves as a ligand-activated transcription factor crucial for regulating fundamental cellular and molecular processes, such as xenobiotic metabolism, immune responses, and cancer development. Notably, a spectrum of endocrine-disrupting chemicals (EDCs) act as agonists or antagonists of AHR, leading to the dysregulation of pivotal cellular and molecular processes and endocrine system disruption. Accumulating evidence suggests a correlation between EDC exposure and the onset of diverse pancreatic diseases, including diabetes, pancreatitis, and pancreatic cancer...
March 29, 2024: International Journal of Molecular Sciences
#29
JOURNAL ARTICLE
Andrew Gaya, Nitesh Rohatgi, Sewanti Limaye, Aditya Shreenivas, Ramin Ajami, Dadasaheb Akolkar, Vineet Datta, Ajay Srinivasan, Darshana Patil
Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate the performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers (PBC). The assay utilizes functional enrichment of CTCs followed by immunofluorescent profiling of organ-specific markers. The performance of the assay was first evaluated in a multicentric case-control study of blood samples from 360 participants, including 188 PBC cases (pre-biopsy samples) and 172 healthy individuals...
April 2, 2024: Cancers
#30
REVIEW
Raymond M Paranal, Laura D Wood, Alison P Klein, Nicholas J Roberts
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is the result of an accumulation of sequential genetic alterations. These genetic alterations can either be inherited, such as pathogenic germline variants that are associated with an increased risk of cancer, or acquired, such as somatic mutations that occur during the lifetime of an individual. Understanding the genetic basis of inherited risk of PDAC is essential to advancing patient care and outcomes through improved clinical surveillance, early detection initiatives, and targeted therapies...
April 12, 2024: Familial Cancer
#31
JOURNAL ARTICLE
Changsong Qi, Rui Guo, Yan Chen, Chenzhen Li, Chang Liu, Miao Zhang, Cheng Zhang, Xiaotian Zhang, Xingguo Hou, Bo Chen, Bing Jia, Zhi Yang, Lin Shen, Hua Zhu
68 Ga-labeled nanobody (68 Ga-NC-BCH) is a single-domain antibody-based PET imaging agent. We conducted a first-in-humans study of 68 Ga-NC-BCH for PET to determine its in vivo biodistribution, metabolism, radiation dosimetry, safety, and potential for quantifying claudin-18 isoform 2 (CLDN18.2) expression in gastrointestinal cancer patients. Methods: Initially, we synthesized the probe 68 Ga-NC-BCH and performed preclinical evaluations on human gastric adenocarcinoma cell lines and xenograft mouse models...
April 11, 2024: Journal of Nuclear Medicine
#32
Motoki Ebihara, Kentoku Fujisawa, Shusuke Haruta, Hironori Uruga, Masaki Ueno
The safety of laparoscopic surgery for advanced gastric and pancreatic cancers has been established individually, but there is little evidence for synchronous cancers. In this case, a 59-year-old man with a history of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) treatment for diffuse large B-cell lymphoma underwent laparoscopic surgery for a suspected pancreatic invasion of advanced gastric cancer. Pathology revealed double cancer of the stomach and pancreas. Laparoscopic total gastrectomy and distal pancreatectomy were successfully performed...
March 2024: Curēus
#33
Ryoichi Miyamoto, Masahiro Shiihara, Mitsugi Shimoda, Shuji Suzuki
We have demonstrated the utility of SYNAPSE VINCENT® (version 6.6; Fujifilm Medical Co., Ltd., Tokyo, Japan), a 3D image analysis system, in semi-automated simulations of the peripancreatic vessels, pancreatic ducts, pancreatic parenchyma, and peripancreatic organs using an artificial intelligence (AI) engine developed with deep learning algorithms. Furthermore, we investigated the usefulness of this AI engine for patients with pancreatic cancer. Here, we present a case of laparoscopic distal pancreatectomy with an extended surgical procedure performed using surgical simulation and navigation via an AI engine...
March 2024: Curēus
#34
JOURNAL ARTICLE
Kanae Inoue, Koh Fukushi, Shota Yamaguchi, Tomonao Taira, Taro Shibuki, Tomoyuki Satake, Kazuo Watanabe, Mitsuhito Sasaki, Hiroshi Imaoka, Shuichi Mitsunaga, Masafumi Ikeda
BACKGROUND: Gemcitabine plus nab-paclitaxel (GnP) therapy has been shown to improve the prognosis in patients with metastatic pancreatic cancer (PC); however, the efficacy and safety of GnP in PC patients with malignant ascites (MA) remains unknown. METHODS: We retrospectively investigated PC patients with peritoneal dissemination who had received GnP as first-line chemotherapy at our institution between March 2015 and August 2021. The following patient data were reviewed: patient characteristics, overall survival (OS), progression-free survival (PFS), objective response rate (ORR), adverse events (AEs), and relative dose intensity (RDI)...
April 4, 2024: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
#35
JOURNAL ARTICLE
Aleksander M Bogdanski, Anke M Onnekink, Akin Inderson, Bas Boekestijn, Bert A Bonsing, Hans F A Vasen, Jeanin E van Hooft, Jurjen J Boonstra, J Sven D Mieog, Martin N J M Wasser, Shirin Feshtali, Thomas P Potjer, Derk C F Klatte, Monique E van Leerdam
OBJECTIVES: The study aimed to investigate the added value of blood glucose monitoring in high-risk individuals (HRIs) participating in pancreatic cancer surveillance. METHODS: HRIs with a CDKN2A/p16 germline pathogenic variant (PV) participating in pancreatic cancer surveillance were included in this study. Multivariable logistic regression was performed to assess the relationship between new-onset diabetes (NOD) and pancreatic ductal adenocarcinoma (PDAC). To quantify the diagnostic performance of NOD as a marker for PDAC, receiver operating characteristic curve with area under the curve (AUC) was computed...
April 10, 2024: Pancreas
#36
JOURNAL ARTICLE
Anna L V Johansson, Simon M Kønig, Siri Larønningen, Gerda Engholm, Niels Kroman, Karri Seppä, Nea Malila, Bjarni Á Steig, Eva Maria Gudmundsdóttir, Elínborg J Ólafsdóttir, Frida E Lundberg, Therese M-L Andersson, Paul C Lambert, Mats Lambe, David Pettersson, Bjarte Aagnes, Søren Friis, Hans Storm
BACKGROUND: Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups. MATERIAL AND METHODS: Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002-2021, and followed for death until 2021...
April 10, 2024: Acta Oncologica
#37
JOURNAL ARTICLE
X Guo, Z Guo, D Sun, L Zou, J Ou, L Yu, Z Lu, H Cao, J Liu
OBJECTIVE: To compare the anti-inflammatory, antitumor and anti-bacterial effects of the single extract (in granules) and the prepared drug in pieces of Forsythia Suspense ( Lianqiao , a traditional Chinese herbal medicine). METHODS: In zebrafish embryo models of CuSO4 exposure, tail transection and LPS microinjection-induced inflammation, the anti-inflammatory effects of 10 μg/mL DEX, single extract of Forsythia Suspense, and the water extract of the prepared drug (400, 600, and 800 μg/mL) were evaluated by observing neutrophil counts, RT- qPCR, HE staining and survival analysis...
March 20, 2024: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
#38
JOURNAL ARTICLE
Rene van Tienhoven, Diahann T S L Jansen, Miso Park, John C Williams, James Larkin, Sergio A Quezada, Bart O Roep
INTRODUCTION: The autoimmune response in type 1 diabetes (T1D), in which the beta cells expressing aberrant or modified proteins are killed, resembles an effective antitumor response. Defective ribosomal protein products in tumors are targets of the anti-tumor immune response that is unleashed by immune checkpoint inhibitor (ICI) treatment in cancer patients. We recently described a defective ribosomal product of the insulin gene (INS-DRiP) that is expressed in stressed beta cells and targeted by diabetogenic T cells...
2024: Frontiers in Immunology
#39
JOURNAL ARTICLE
Gayle Caruana, Robert Cachia, Sara Micallef, Matthew Sammut, Josephine Psaila
Hepatoid adenocarcinoma (HAC) of the mediastinum is a rare extrahepatic tumour that pathologically and morphologically resembles hepatocellular carcinoma. Extrahepatic HACs primarily occur in the stomach, ovaries, lung, gallbladder, pancreas and uterus. Patients with mediastinal HAC tend to be male smokers over forty years of age. Clinical symptoms of HAC are non-specific and varied in nature; therefore, diagnosis can be challenging and often delayed. Diagnostic investigations encompass haematological, radiological and histological assessment...
April 9, 2024: BMJ Case Reports
#40
JOURNAL ARTICLE
Chetan Parmar, Kamal Abi Mosleh, Pauline Aeschbacher, Thorvardur R Halfdanarson, Travis J McKenzie, Raul J Rosenthal, Omar M Ghanem
BACKGROUND: Metabolic and bariatric surgery (MBS) is a potent intervention for addressing obesity-related medical conditions and achieving sustainable weight loss. Beyond its conventional role, MBS has demonstrated potential to serve as a transitional step for patients requiring various interventions. However, the implications of MBS in the context of neoplasia remain understudied. OBJECTIVES: To explore the feasibility of MBS as a possible attempt to reduce surgical and treatment risks in patients with benign tumors or low-grade cancers...
March 7, 2024: Surgery for Obesity and Related Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
